The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs
NewS Archive
Fierce Biotech
Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies
BioSpace
Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)
BioSpace
Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies
“We believe that this technology has broad potential and we are excited to apply it in new areas…”
FierceBiotech
Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies
Wall Street Journal
Healthcare Investor Digitalis Ventures Nets $300 Million Fund